Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches

Your place for beaking medical news and career advice from top medical recruiters

Strong innovation momentum continued in Q2, culminating in key launches

  • Entresto approved and launched in US (July) for chronic heart failure with reduced ejection fraction
  • Glatopa, the first generic competitor to Copaxone® 20mg, approved and launched in US
  • Approvals for Zykadia (EU) and Promacta (US), and positive CHMP opinion for Farydak
  • Positive data including Tafinlar/Mekinist combination in metastatic melanoma, Afinitor in GI and lung NET and Cosentyx in ankylosing spondylitis

Growth Products continued to drive Q2 performance and rejuvenate portfolio

  • Growth Products[3] grew 24% (USD) to USD 4.4 billion, or 35% of net sales
  • Strong performance in Emerging Growth Markets[3] (+8% cc)

Outlook 2015 for continuing operations confirmed:

  • Continuing operations net sales expected to grow mid-single digit (cc); core operating income expected to grow ahead of sales at a high-single digit rate (cc)
  • To reflect first half performance, Novartis raises Sandoz FY guidance to high single digit sales growth (cc), lowers Alcon FY guidance to low single digit sales growth (cc)

Schryver Medical, a Portfolio Company of Revelstoke Capital Partners, Completes Acquisition of Main Street Clinical Laboratory, Inc. and On-Site Imaging Solutions, Inc

DENVER–(EON: Enhanced Online News)–Schryver Medical Sales and Marketing, LLC (“Schryver”), a portfolio company of Revelstoke Capital Partners (“Revelstoke”), a Denver-based private equity firm, has completed the acquisitions of Main Street Clinical Laboratory, Inc. (“Main Street”) and On-Site Imaging Solutions, Inc. (“On-Site”).  read more

Nestlé Skin Health Launches SHIELD Center in Shanghai to Enable and Advance Healthy and Active Ageing

SHANGHAI, China–(EON: Enhanced Online News)–Nestlé Skin Health, global leader focused on enhancing the quality of life by delivering science-based solutions for the health of the skin, today launched its new Skin Health Investigation, Education and Longevity Development (SHIELD) Center in Shanghai. The Shanghai SHIELD center will establish China as one of the anchors in Nestlé Skin Health’s global innovation network and is built to foster breakthroughs and collaboration in skin health through medical investigation, education and applications related to the convergence of technologies and bio-informatics. This global initiative is driven by the growing, changing and still underappreciated needs of an increasingly ageing population and the need for a life course of healthy skin to enhance well-being. read more

Novacyt Completes €2m private placement to support second half sales growth

PARIS & CAMBRIDGE, England–(EON: Enhanced Online News)–Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics reported earlier its strong first-half sales performance across the Group and the completion of €3.5m in bond refinancing. Today, Novacyt is pleased to announce a further private placement financing of €2m. read more

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.